Novo Holdings A/S’s Alnylam Pharmaceuticals ALNY Stock Holding History

Novo Holdings A/S’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-118,383	Closed	-$32.6M	–	35
2024 Q3	$32.6M	Hold	118,383	–	–	1.62%	19
2024 Q2	$28.8M	Hold	118,383	–	–	1.55%	21
2024 Q1	$17.7M	Hold	118,383	–	–	1.22%	27
2023 Q4	$22.7M	Hold	118,383	–	–	1.4%	25
2023 Q3	$21M	Hold	118,383	–	–	1.55%	24
2023 Q2	$22.5M	Hold	118,383	–	–	1.74%	19
2023 Q1	$23.7M	Buy	118,383 +6,383	+6%	+$1.34M	1.56%	20
2022 Q4	$26.6M	Buy	112,000 +12,000	+12%	+$2.56M	1.66%	21
2022 Q3	$20M	Buy	100,000 +15,200	+18%	+$2.9M	0.95%	22
2022 Q2	$12.4M	Buy	84,800 +59,800	+239%	+$8.48M	0.61%	29
2022 Q1	$4.08M	Hold	25,000	–	–	0.22%	47
2021 Q4	$4.24M	Hold	25,000	–	–	0.2%	46
2021 Q3	$4.72M	Sell	25,000 -9,679	-28%	-$1.82M	0.24%	43
2021 Q2	$5.88M	Buy	+34,679	New	+$5.08M	0.26%	47

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Novo Holdings A/S's ALNY Position: Q4 2024 in Review

Novo Holdings A/S sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 118,383 shares — an estimated $32.6M sold.

Novo Holdings A/S first reported a position in ALNY in Q2 2021 and held it in 14 quarters. The position peaked at $32.6M in Q3 2024. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Novo Holdings A/S reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Novo Holdings A/S sold 118,383 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $32.6M.
Novo Holdings A/S first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 14 quarters.
Novo Holdings A/S's Alnylam Pharmaceuticals position peaked at $32.6M in Q3 2024.
594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Novo Holdings A/S's 13F filing for Q4 2024, filed 14 Feb 2025.